Ocular Application of the Kinin B₁ Receptor Antagonist LF22-0542 Inhibits Retinal Inflammation and Oxidative Stress in Streptozotocin-Diabetic Rats

Mylène Pouliot¹,², Sébastien Talbot², Jacques Sénécal², Florence Dotigny¹, Elvire Vaucher¹, Réjean Couture²* ¹École d’optométrie, Université de Montréal, Montréal, Canada, ²Département de Physiologie, Faculté de Médecine, Université de Montréal, Montréal, Canada

Abstract

Purpose: Kinin B₁ receptor (B₁R) is upregulated in retina of Streptozotocin (STZ)-diabetic rats and contributes to vasodilation of retinal microvessels and breakdown of the blood-retinal barrier. Systemic treatment with B₁R antagonists reversed the increased retinal plasma extravasation in STZ rats. The present study aims at determining whether ocular application of a water soluble B₁R antagonist could reverse diabetes-induced retinal inflammation and oxidative stress.

Methods: Wistar rats were made diabetic with STZ (65 mg/kg, i.p.) and 7 days later, they received one eye drop application of LF22-0542 (1% in saline) twice a day for a 7 day-period. The impact was determined on retinal vascular permeability (Evans blue exudation), leukostasis (leukocyte infiltration using Fluorescein-isothiocyanate (FITC)-coupled Concanavalin A lectin), retinal mRNA levels (by qRT-PCR) of inflammatory (B₁R, iNOS, COX-2, ICAM-1, VEGF-A, VEGF receptor type 2, IL-1β and HIF-1α) and anti-inflammatory (B₂R, eNOS) markers and retinal level of superoxide anion (dihydroethidium staining).

Results: Retinal plasma extravasation, leukostasis and mRNA levels of B₁R, iNOS, COX-2, VEGF receptor type 2, IL-1β and HIF-1α were significantly increased in diabetic retinas compared to control rats. All these abnormalities were reversed to control values in diabetic rats treated with LF22-0542. B₁R antagonist also significantly inhibited the increased production of superoxide anion in diabetic retinae.

Conclusion: B₁R displays a pathological role in the early stage of diabetes by increasing oxidative stress and pro-inflammatory mediators involved in retinal vascular alterations. Hence, topical application of kinin B₁R antagonist appears a highly promising novel approach for the treatment of diabetic retinopathy.

Introduction

Recent findings suggest a role for the kallikrein-kinin system in the development of diabetic retinopathy [1,2,3]. Kinins are important inflammatory mediators involved in tissue edema, leukocytes infiltration, vasodilation and regulation of local blood flow [4]. These peptides are produced at the site of inflammation and exert their effects through the activation of two G-protein-coupled receptors named B₁ (B₁R) and B₂ (B₂R) [5,6]. B₁R is constitutively expressed and mediates mainly the acute effects of kinins due to its rapid desensitization. In contrast, B₂R is expressed at very low levels in physiological conditions. This inducible receptor is upregulated in response to tissue injury, by pro-inflammatory cytokines or by the oxidative stress associated to hyperglycemia. The B₁R is involved in the chronic phase of the inflammatory response which is compatible with its low desensitization mechanism [7,8,9]. Bradykinin (BK) and kallidin (KD) mediate the action of B₁R while their kininase I metabolites des-Arg⁹-BK and des-Arg¹⁰-KD are the preferential agonists for B₁R [7,8]. The activation of these receptors induces the release of nitric oxide (NO), prostaglandins and pro-inflammatory cytokines [4,10,11].

Most components of the kallikrein-kinin system have been identified in the human, rabbit and rat retina [12,13,14,15]. Particularly, B₁R was found overexpressed in the retina of Streptozotocin (STZ)-diabetic rats through a mechanism involving oxidative stress [16,17]. In STZ-diabetic rats, B₁R mediates vasodilation of ex vivo retinal microvessels [16] and contributes to the breakdown of the blood-retinal barrier in vivo [17]. Collectively, these results suggest a pathological role for B₁R in the development of retinal damage in diabetes and the progression of diabetic retinopathy.

Diabetic retinopathy is characterized by vascular alterations including retinal blood flow changes, endothelial cells dysfunction,
breakdown of the blood-retinal barrier, ischemia and neovascularisation [18]. Oxidative stress and inflammatory processes are thought to contribute largely to the development of the disease [19,20,21]. Hyperglycemia induces the production of reactive oxygen species (ROS) and the expression of many pro-inflammatory factors in the diabetic retina including inducible nitric oxide synthase (iNOS), interleukin-1β (IL-1β), cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) [20]. Vasodilatation, increased vascular permeability and adhesion of inflammatory cells to the vascular wall are also part of the inflammatory response occurring in the retina during diabetes [22,23,24].

The present study aims at determining whether topical ocular application of LF22-0542, a non-peptide water soluble B1R antagonist, could reverse diabetes-induced retinal inflammation and oxidative stress. Our data show that the enhanced retinal vascular permeability, leukostasis, the enhanced expression of several inflammatory mediators and higher production of superoxide anion levels were significantly decreased in the retina of STZ-diabetic rats treated with LF22-0542. This provides the first demonstration that ocular application of a kinin B1R antagonist could be an effective strategy in the treatment of diabetic retinopathy.

Materials and Methods

STZ-diabetic rats

All experimental methods and animal care procedures were approved by the animal care committee of the Université de Montréal (protocol 09-030), in accordance with the Canadian Council on Animal Care. Male Wistar rats weighting 200–250 g were purchased from Charles River (St-Constant, QC, Canada) and housed two per cage in a room under controlled temperature (23°C), humidity (50%) and lighting (12-hour light/dark cycle) with food and water provided ad libitum. Rats were rendered diabetic by a single i.p. injection of Streptozotocin (STZ, Zanosar 65 mg/kg, Sigma-Aldrich, Oakville, ON, Canada). Age-matched control rats were injected with vehicle (sterile saline 0.9%, pH 7.4). Glucose concentrations were measured in blood samples obtained from the tail vein with a commercial blood glucose analyzer (Accusoft; Roche Diagnostics, Laval, QC, Canada). Only STZ-treated rats with blood glucose concentration higher than 20 mmol/L were considered as diabetic and included in the study. Glycemia and body weight were recorded twice a week and on the day of the experiment.

Topical ocular treatment with B1R antagonist LF22-0542

Seven days after diabetes induction, rats were treated twice a day (8:30 AM and 3:30 PM) with one eye drop application of the water soluble B1R antagonist LF22-0542 (1% in saline) for a 7-day period. LF22-0542 (N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-methyl]-2-[2-[[4-methoxy-2,6 dimethylphenyl]sulfonyl]methylamino]ethoxy]-N-methyl-acetamide, fumarate) is a competitive non-peptide B1R antagonist which was synthesized and provided by Fovea Pharmaceuticals SA, Paris, France. The chemical structure of LF22-0542 is presented in Figure 1. LF22-0542 showed high affinity for human and mouse B1R with virtually no affinity for the human B2R; a selectivity index of at least 4000 times was obtained when LF22-0542 was profiled throughout binding or cell biology assays on 64 other G-protein-coupled receptor, 10 ion channels, and seven enzymes [25]. LF22-0542 blocked pain behavior in various inflammatory and neuropathic pain models in rats and mice and was found inactive in B1R knockout mice models of inflammatory pain [25,26,27]. Fresh solution was prepared daily by dissolving the compound in saline 0.9% and sterilizing the solution by filtration (0.20 μm mesh). For ocular instillation, rats were firmly maintained and a drop of solution (10 μl) was instilled on the surface of the eye using a micropipette. Animals were maintained 10 s in order to make sure that the drop effectively remained on the surface of the eye. Every day, the rats were visually inspected to detect the presence of ocular irritation such as redness, porphyrin secretion or corneal opacity. All end points were determined on the last day of treatment.

Measurement of retinal vascular permeability

Retinal vascular permeability was assessed using Evans blue dye extravasation technique as previously described [17]. Rats were anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and a catheter (Micro-Renathane, I.D. 0.040”, O.D. 0.020”, Braintree Scientific, Braintree, MA, USA) was inserted into the right femoral vein. Evans blue dye (45 mg/ml in saline) (Sigma-Aldrich, Oakville, ON, Canada) was injected i.v. over 10 s. The dye was allowed to circulate for 2 h and then saline (25 ml) was infused through the left ventricle, to wash out intravascular dye. Following enucleation, retinae were dissected out and immediately weighed. Evans blue dye was then extracted by incubating each retina in 1 ml formamide (Sigma-Aldrich, Oakville, ON, Canada) for 18 h at 70–75°C. The fluorescence of Evans blue was measured using a spectrophurometer (Spxc 1681 0.22 mm, Horiba JobinYvon Inc, Edison, NJ, USA) at 620 nm (excitation) and 680 nm (emission).

Measurement of retinal leukostasis

Rats were anesthetized with isoflurane, the chest cavity was opened and a 16G cannula was inserted into the left heart ventricle. Rats were perfused with phosphate buffer saline (PBS) over 1 min (35 ml/min) to eliminate erythrocytes and non-adherent leukocytes. Fluorescein-isothiocyanate (FITC)-coupled Concanavalin A lectin (20 μg/ml) in PBS, 5 mg/kg; Vector Labs, Burlington, ON, Canada) was infused at 30 ml/min to label adherent leukocytes and vascular endothelial cells. Rats were perfused with 4% paraformaldehyde over 4 min followed by 1% Albumin in PBS over 1 min and PBS over 2 min (35 ml/min). Retinae were dissected out, flat mounted on a glass slide and imaged using a fluorescence microscope (Leica microsystems Co., Germany). The total number of leukocytes in each retina was determined under microscope examination at 40×.

Measurement of retinal inflammatory mediators by quantitative RT-PCR

Rats were anaesthetized with sodium pentobarbital (60 mg/kg, i.p.) and the eyes were dissected out. The retinae were isolated under RNAlater stabilization reagent (QIAGEN, Valencia, CA, USA). Total RNA was extracted from retinae using a commercial...
kit (QIAGEN, Valencia, CA, USA). First-strand cDNA synthesized from 400 ng total RNA with random hexamer primers was used as template for each reaction with the Quantitect Rev Transcription Kit (QIAGEN). SYBR Green-based real-time quantitative PCR using Mx3000p device for signal detection (Stratagene, La Jolla, CA, USA) was performed as previously described [17]. PCR was performed in SYBR Green Master mix (QIAGEN) with 300 nM of each primer. The primer pairs designed by Vector NTI software are shown in Table 1. For standardization and quantification, rat 18S was amplified simultaneously. PCR conditions were as follows: 95°C for 15 min, followed by 46 cycles at 94°C for 15 s, 60°C for 30 s and 72°C for 30 s. The cycle threshold (Ct) value represents the cycle number at which a fluorescent signal rises statistically above background. The relative quantification of gene expression was analyzed by the 2−ΔΔCt method [28].

Measurement of superoxide anion production in the retina
Rats were sacrificed with CO2 inhalation and the eyes were dissected out, frozen in isopentane (−55°C), cut into 20-μm thick sections and placed on glass slides. Superoxide anion (O2−) production was measured in retina using the oxidative fluorescent dye dihydroethidium (DHE) as described earlier [29]. Cells are permeable to hydroethidine and, in the presence of O2, it is oxidized to fluorescent ethidium bromide (EtBr) which is trapped by intercalation with DNA. EtBr is excited at 518 nm with an emission spectrum of 605 nm. Dihydroethidium (2 μM) (Sigma-Aldrich, Oakville, ON, Canada) was applied to 20-μm thick eye sections and the slides were then incubated in a light-protected humidified chamber at 37°C for 30 min. Nuclei of retinal cells were stained with TO-PRO-3 (Molecular Probes, Eugene, Ore, USA). Images were obtained with a Leica TCS SP confocal microscope equipped with an argon laser (Leica microsystems Co., Germany). Tissues from each experimental group were processed and imaged in parallel. Laser settings were identical for acquisition of images from all sections. Leica LCS Lite software was used to quantify the mean pixel energy of DHE and TO-PRO-3 in the retinal ganglion cells (RGC) layer, the inner nuclear layer (INL) and the outer nuclear layer (ONL). Data were expressed as the mean pixel energy ratio between DHE and TO-PRO-3 from an average of 10 nuclei in the RGC layer or 20 nuclei in the INL and ONL for each retinal image quantified in 3 rats.

Statistical analysis
Data were expressed as mean ± s.e.m. and n represents the number of rats used in each experiment. Multiple comparisons between groups were performed using the non-parametric Mann-Whitney test for retinal leukostasis. One-way ANOVA and the Bonferroni post-hoc test were used for Table 2 data, vascular permeability, expression of inflammatory mediators and superoxide anion measurement. Only probability values (P) less than 0.05 were considered to be statistically significant.

Results
Physiological parameters
As shown in Table 2, blood glucose concentration was significantly increased in STZ-diabetic rats at the time of sacrifice when compared to age-matched control rats (P<0.001). One-week

Table 1. Primers list.

<table>
<thead>
<tr>
<th></th>
<th>Sequence</th>
<th>Position</th>
<th>Gen Bank</th>
</tr>
</thead>
<tbody>
<tr>
<td>B1R</td>
<td>Forward 5′ GCA GCG CTT AAC CAT AGC GGA AAT</td>
<td>3′ 367</td>
<td>- 390 NM_030851</td>
</tr>
<tr>
<td></td>
<td>Reverse 5′ GAA ACG GTT CCC GAT GTT</td>
<td>3′ 454</td>
<td>- 431</td>
</tr>
<tr>
<td>B2R</td>
<td>Forward 5′ AGG TGC TGA GGA ACA AGA AGA TGA</td>
<td>3′ 882</td>
<td>- 905 NM_173100</td>
</tr>
<tr>
<td></td>
<td>Reverse 5′ TCC AGG AAG GTG ATG TTC TGG AAA</td>
<td>3′ 990</td>
<td>- 967</td>
</tr>
<tr>
<td>iNOS</td>
<td>Forward 5′ TGA TCT TGT GCT GGA GGT GAT CAT</td>
<td>3′ 1150</td>
<td>- 1173 NM_012611</td>
</tr>
<tr>
<td></td>
<td>Reverse 5′ TGT AGC GCT GTG ATG CAT ACA AGT</td>
<td>3′ 1349</td>
<td>- 1326</td>
</tr>
<tr>
<td>eNOS</td>
<td>Forward 5′ TAT TTG ATG CTC GGG ACT GCA GGA</td>
<td>3′ 587</td>
<td>- 610 NM_021838</td>
</tr>
<tr>
<td></td>
<td>Reverse 5′ AGG AAG ATT GCC TCG GTG TGT TGC</td>
<td>3′ 678</td>
<td>- 655</td>
</tr>
<tr>
<td>COX-2</td>
<td>Forward 5′ GCA TTC TTT GCC CAG CAT TAC ACT</td>
<td>3′ 677</td>
<td>- 700 U03389</td>
</tr>
<tr>
<td></td>
<td>Reverse 5′ TTT AAG GCC CAT TGG CCC AGT</td>
<td>3′ 744</td>
<td>- 751</td>
</tr>
<tr>
<td>ICAM-1</td>
<td>Forward 5′ TGC AGG TGA ACT GCT TCT CCT CTT</td>
<td>3′ 161</td>
<td>- 184 NM_012967</td>
</tr>
<tr>
<td></td>
<td>Reverse 5′ AGC TTC CAG TGT TGT CCA CTC CAT</td>
<td>3′ 263</td>
<td>- 240</td>
</tr>
<tr>
<td>VEGF-A</td>
<td>Forward 5′ TCA CCA AAG CCA CCA CAT AGG AGA</td>
<td>3′ 1219</td>
<td>- 1242 BC168708</td>
</tr>
<tr>
<td></td>
<td>Reverse 5′ TTA CAC GTC TGG TGG TCA ACA</td>
<td>3′ 1371</td>
<td>- 1348</td>
</tr>
<tr>
<td>VEGF-R2</td>
<td>Forward 5′ AGT GGC TAA GGG CAT GGA GTT TT</td>
<td>3′ 3269</td>
<td>- 3292 U93306</td>
</tr>
<tr>
<td></td>
<td>Reverse 5′ GGG CCA AGC CAA AGT CAT AGA TTT</td>
<td>3′ 3387</td>
<td>- 3364</td>
</tr>
<tr>
<td>IL-1β</td>
<td>Forward 5′ TGT CAC TCA TTG TGG TGG TGG AGA</td>
<td>3′ 247</td>
<td>- 270 NM_031512</td>
</tr>
<tr>
<td></td>
<td>Reverse 5′ TGG GAA CAT CAC ACA CTA GCA GGT</td>
<td>3′ 411</td>
<td>- 388</td>
</tr>
<tr>
<td>HIF-1α</td>
<td>Forward 5′ TAG ACT TGG AAA TGG TGG TCC CCT</td>
<td>3′ 1693</td>
<td>- 1716 NM_024359</td>
</tr>
<tr>
<td></td>
<td>Reverse 5′ TGG CAGTGA CAG TGA TGG TAG TTG</td>
<td>3′ 1863</td>
<td>- 1840</td>
</tr>
<tr>
<td>IL-18</td>
<td>Forward 5′ TCA ACT TCT GAT GGT AGT CCG CGT</td>
<td>3′ 363</td>
<td>- 385 X01117</td>
</tr>
<tr>
<td></td>
<td>Reverse 5′ TCC TTG GAT GTG GAT GCC GTT TCT</td>
<td>3′ 470</td>
<td>- 447</td>
</tr>
</tbody>
</table>

doi:10.1371/journal.pone.0033864.t001
Table 2. Effect of diabetes and LF22-0542 on glycaemia and body weight.

<table>
<thead>
<tr>
<th></th>
<th>Glycaemia (mmol/L)</th>
<th>Body weight (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control+Vehicle (n=7)</td>
<td>5.5 ± 0.2</td>
<td>356 ± 6</td>
</tr>
<tr>
<td>Control+LF22-0542 (n=6)</td>
<td>5.1 ± 0.2</td>
<td>355 ± 5</td>
</tr>
<tr>
<td>STZ+Vehicle (n=5)</td>
<td>26.8 ± 2.9**</td>
<td>295 ± 9***</td>
</tr>
<tr>
<td>STZ+LF22-0542 (n=7)</td>
<td>27.7 ± 2.9***</td>
<td>274 ± 5***</td>
</tr>
</tbody>
</table>

Values are mean ± s.e.m. unless indicated.
***P<0.001, significantly different from control group.
doi:10.1371/journal.pone.0033864.t002

eye drops application of LF22-0542 had no effect on glycaemia in both control and STZ-diabetic rats (P>0.05). Body weight was significantly reduced in STZ-diabetic rats treated or not with LF22-0542 compared to controls (P<0.001). Treatment of diabetic rats with LF22-0542 had no effect on body weight when compared to diabetic rats treated with the vehicle (P>0.05). Control and STZ-diabetic rats that received eye drops of LF22-0542 did not show symptoms of ocular irritation (redness or corneal opacity) or the presence of porphyrin secretion around the eyes during the whole period of treatment.

Effect of LF22-0542 on retinal vascular permeability

Evans Blue extravasation (µg/g of fresh tissue) was significantly increased by 31% in STZ-diabetic rats compared to control rats (P<0.05). Topical ocular administration of LF22-0542 reversed retinal vascular hyperpermeability to control values in STZ-diabetic rats (P<0.05) (Figure 2).

Effect of LF22-0542 on retinal leukostasis

Retinal adherent leukocytes were labelled with FITC-Concanavalin A lectin (Figure 3A). Total number of adherent leukocytes in the retinal wall was significantly increased in STZ-diabetic rats compared to control rats (P<0.05) (Figure 3B). One-week eye drops administration of LF22-0542 to diabetic rats significantly decreased retinal leukostasis (P<0.05). B1R antagonist treatment had no significant effect on leukocytes number in control retina (P>0.05).

Effect of LF22-0542 on oxidative stress

Production of superoxide anion (O2−) in the retina measured with the oxidative fluorescent dye dihydroethidine is shown in Figure 5. DHE staining of STZ-diabetic retinal sections displayed a higher intensity of fluorescence than controls (Figure 5A). Quantification of the O2− retinal levels (mean pixel intensity ratio of DHE staining versus TO-PRO-3) showed a significant increase in the retinal ganglion cells layer (RGC) (P<0.01), the inner nuclear layer (INL) (P<0.01) and the outer nuclear layer (ONL) (P<0.01) of STZ-diabetic rats compared to control rats (Figure 5B). Importantly, one-week topical administration of LF22-0542 to STZ-diabetic rats markedly reduced O2− levels in the 3 retinal nuclear layers (P<0.05). Administration of LF22-0542 had no significant effect on basal production of O2− in the retina of control animals (P>0.05).

Discussion

This study provides the first demonstration that prolonged ocular application of a water soluble non-peptide kinin B1R antagonist is an effective and non-toxic approach to inhibit diabetes-induced retinal inflammation and oxidative stress. The results clearly show that the B1R antagonist reversed the increased vascular permeability, leukostasis, the enhanced expression of several inflammatory mediators and the higher production of reactive oxygen species.

Retinal vascular permeability

Breakdown of the blood-retinal barrier appears early in the progression of diabetic retinopathy and often leads to the development of macular edema which is a major cause of visual impairment in diabetic patients [30,31]. Retinal vascular permeability has been largely studied in experimental models of diabetes and evidence was provided that breakdown of the blood-retinal barrier occurs as early as one week following diabetes induction in rats [24,32]. The present study shows that 7-day eye drops application of the B1R antagonist LF22-0542 completely reversed increased retinal vascular permeability in 2-week STZ-diabetic rats. This is consistent with the inhibition of retinal plasma extravasation following a 7-day i.v. treatment with the peptide B1R antagonist R-715 in STZ-diabetic rats [17]. Likewise, s.c. or i.v. injection of the peptide B1R antagonist R-954 reversed the enhanced vascular permeability in the retina and other target tissues in mice and rats treated with STZ 1 and 4 weeks earlier [33,34,35]. Our results are also consistent with a previous study that showed a decrease in retinal vascular permeability following treatment with a selective plasma kallikrein inhibitor in STZ-diabetic rats [36].

The alleviation of enhanced vascular permeability by B1R antagonism could be explained by the concomitant reduction in gene expression of iNOS, COX-2 and VEGF-R2 in rats treated with LF22-0542. Nitric oxide pathway, prostaglandins and VEGF...
are known to play a role in breakdown of the blood-retinal barrier through a mechanism involving the upregulation of intercellular adhesion molecules (ICAM-1) and the downregulation of tight junctions proteins in the retinal vasculature [37,38,39]. Moreover, B1R is known to be expressed on retinal vessels and could therefore directly increase vascular permeability through the release of NO and prostaglandins following its activation.

In addition to supporting a key role for kinin B1R in retinal vascular permeability, our results demonstrate that LF22-0542 reached the rat retina when given by eye drops application. This is the first use of a B1R antagonist as ocular treatment. LF22-0542 had a specific action at the ocular level and was not detected in the blood circulation after prolonged ocular administration in rabbits (unpublished data). Therefore, eye drops application provides the advantage of avoiding systemic effects for potential clinical treatment. Moreover, topical treatment is the less invasive route of administration for treatment of ocular disease and would be beneficial for the treatment of diabetic retinopathy. Current therapies for these patients include laser induced retinal photocoagulation and repetitive intravitreal injections of anti-VEGF molecules, which are very expensive and associated with significant risks of infection, retinal lesion and pain. These treatments help to reduce the progression of diabetic retinopathy in advanced stages of the disease but are not curative. Topical B1R antagonist is therefore a very promising approach for the treatment of early pathological changes in the diabetic retina.

Leukostasis
Leukocytes adhesion to the retinal vasculature is thought to be associated with endothelial cell death, capillary occlusion and increased vascular permeability, which all contribute to the progression of diabetic retinopathy [21,22]. Following their adherence to the retinal vessels of diabetic rats, leukocytes exit the vasculature and transmigrate to the neural retina [24,40,41]. Our data suggest that B1R antagonism is a possible therapeutic strategy for reversing retinal leukostasis and the associated vascular alterations in diabetes. Previously, B1R has been shown to be involved in all 3 phases of the leukocyte recruitment process in inflamed tissue [42,43]. B1R agonist caused leukocytes rolling, adhesion and emigration in mouse mesenteric postcapillary venules [44] and leukocytes migration and infiltration in the pleural cavity [45,46].

Leukocytes bind to ICAM on the surface of endothelial cells to adhere to the vasculature. Previous studies reported that the increased number of adherent leukocytes in the diabetic retina is mediated by the concomitant increase of ICAM-1 expression in the retinal vasculature [24,47]. Importantly, our results show a reduced level of expression of ICAM-1 in the retina of STZ-diabetic rats treated with LF22-0542 in parallel with the decrease of leukostasis.

Expression of B1R and B2R
Real time RT-PCR analysis revealed that B1R was significantly upregulated in the retina of STZ-diabetic rats which is consistent with the increased density of B1R binding sites previously reported by autoradiography [16] and with the increased B1R protein expression by western blot [48]. The activation of B1R is known to induce the production of pro-inflammatory cytokines that can directly cause the expression of B1R. The prolonged ocular treatment with B1R antagonist inhibits both the inflammatory response and expression of B1R. Level of B2R gene expression in the retina of diabetic rats was slightly but not significantly increased in the diabetic retina, yet it was reduced to control values in diabetic rats treated with LF22-0542. Further studies are needed to clarify the contribution of B2R in the effects mediated by B1R blockade.

Expression of inflammatory mediators
Our results demonstrate that B1R plays a central role in retinal inflammation by interacting with many pro-inflammatory factors involved in vascular alterations. mRNA levels of IL-1β, COX-2 and VEGF-R2 were increased in diabetic retinas compared to
control rats and were restored to control values with LF22-0542 treatment. Previous studies also reported increased expression of IL-1β and COX-2 in the retina of diabetic rats [49,50]. VEGF is also known to play a central role in the development of diabetic retinopathy since it is involved in neovascularisation and increased vascular permeability [38,39,50]. Moreover, our results show that
Oxidative stress

Compelling evidence suggests that oxidative stress induced by hyperglycemia plays an important role in the development of vascular alterations in the retina [19,55]. Oxidative stress is produced by multiple cell types in the retina including endothelial cells, pericytes and glial cells [19,56,57,58]. In agreement with previous studies conducted in diabetic mice and rats [56,59,60], we found increased production of superoxide anion in the retina of STZ-diabetic rats, which was reversed by LF22-0542. Since retinal B1R overexpression was reversed by an antioxidant in STZ-diabetic rats [17], it was concluded that the oxidative stress associated with hyperglycemia is responsible for the induction of B1R in the retina. Herein, data suggest that the stimulation of B1R can perpetuate the harmful production of ROS, and therefore the blockade of B1R should interrupt this deleterious vicious cycle, since inflammation can induce oxidative stress and vice versa. This is in keeping with other relevant findings. In cardiac tissue, nitrotyrosine protein level, a marker of oxidative stress, was reduced in B1R knockout diabetic mice [61]. In a rat model of insulin resistance, one-week treatment with the orally active B1R antagonist SSR240612 reversed increased levels of superoxide anion and B1R expression in the aorta through the inhibition of NADPH oxidase [62].

The alleviation of oxidative stress in the diabetic retina by B1R antagonist could explain the reduction in the expression of inflammatory mediators. It is known that oxidative stress resulting from the production of ROS triggers the activation of the nuclear transcription factor kappa B (NF-κB) [63]. NF-κB is a widely expressed inducible transcription factor and an important regulator of many genes involved in inflammatory and immune responses including IL-1β, ICAM-1, iNOS, COX-2 and B1R [20,64]. Therefore, by reducing oxidative stress in the retina, B1R antagonist could indirectly inhibit NF-κB activation and thereby inflammation, including the expression of its own receptor.

Conclusion

The findings suggest that B1R is involved in the inflammatory cascade leading to retinal vascular damage in the early stages of diabetes. The oxidative stress associated with hyperglycemia induces the expression of B1R in the retina. In turn, the activation of B1R may perpetuate the production of ROS to enhance the expression of vascular pro-inflammatory mediators (COX-2, IL-1β, ICAM-1, VEGF and HIF-1α). Those mediators in concert with B1R could enhance leukostasis and vascular permeability in the diabetic retina. These pathological events are likely to contribute to the development of diabetic retinopathy. Hence, the ocular application of LF22-0542, a highly potent antagonist at human B1R, represents a promising therapeutic approach in diabetic retinopathy.
**Acknowledgments**

PhD Stundentship Awards were obtained from the Foundation Fighting Blindness (MP), the FRSQ (MP, ST) and the Canadian Institutes of Health Research (ST). Authors are thankful to Denis Latendresse for the artwork.

**References**